Gene Therapy Alters Immune Cells For Treatment Of Advanced Melanoma
SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma
Long-Term Remissions Shown With Chemo Plus Radiation
Raloxifene Protects Women At High or Low Risk of Disease
Study Needs 23,000 Women Whose Sisters Have Cancer
Tamoxifen: No Mortality Benefit For Most “High Risk” Women
Breast Density As Important As Age In Determining Risk
Ovariectomy Without HRT Increases Death Rate
NCI-Approved Clinical Trials
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - In The Headlines: Private funding can’t replace federal funding—but it can help